Marshall University Participates in Phase 3 AURORA Late State Fatty Liver Disease Clinical Trial

Mar 13, 2019 | Fatty Liver, NASH, Non-Alcoholic Steatohepatitis

Fatty Liver Disease

Marshall University and the Joan C. Edwards School of Medicine reports that they are participating in a clinical trial investigating a drug for late-state liver disease.  Non-Alcoholic Steatohepatitis, also known as NASH, is one of the most serous live complications that originate from obesity. Located in West Virginia, the population faces a growing number of NASH cases.  The Centers for Disease Control (CDC) reports that West Virginia ranked 9th in the nation in 2017 for NASH.

Sponsored by Allergan, the trial is known as AURORA. It is being conducted to evaluate the efficacy and safety of the investigational drug for the treatment of liver fibrosis in adult patients 18 to 75 with NASH.  Participants will attend regularly scheduled study visits with Marshall.  For more on Marshall’s clinical trials information see their Clinical Research Center. 

The clinical research includes prominent centers:

  • Appalachian Clinical and Translational Science Institute (ACTS1)
  • Appalachian Center for Cellular Transport in Obesity Related Disorders (ACCORD)
  • Marshall Institute for Interdisciplinary Research (MIIR)
  • West Virginia IDeA Network of Biomedical Research Excellence (WV-INBRE)

Lead Research/Investigator

Uma Sundaram, M.D


Pin It on Pinterest